Sartorius Stedim Biotech: stock declines 2% after 15% surge in one month
Sartorius Stedim Biotech pauses mid-session, in a retreating SBF 120. The stock emerges from a series of supported sessions that had driven it past several technical thresholds since late September. Today's decline occurs at the contact of its resistance level.
A measured pullback that keeps the stock firmly positioned above its three moving averages
The bioprocess equipment manufacturer retreats 2.01% to €214.40, compared to €218.80 the previous day, while the SBF 120 declines 0.77%. It ranks in the lower portion of the index without being among the heaviest decliners. This movement does not, however, undermine the recent trajectory: the stock remains 4.97% above its 20-day moving average and 17.60% above its 200-day moving average, and displays a 19.58% gain over three months.
The level of €218.80, which corresponds to yesterday's close and the current resistance, is limiting any new advance for now. The stock had broken through €217.20 on October 6, and today's decline brings it just below this zone. The RSI at 67 reflects a stock already well-oriented, approaching levels where profit-taking becomes frequent.
A P/E ratio of 43 and half-year targets that frame the valuation
On the company's financial figures, Sartorius Stedim Biotech had gained 2% on October 2 in the wake of analyst upgrades, which sheds light on the dynamics of recent weeks. According to the consensus of surveyed analysts, the stock trades at approximately 43 times current fiscal year earnings and 35.7 times the following fiscal year earnings. During the H1 2026 publication on July 22, guidance retained revenue of €3,153.8 million and EBITDA of €989.2 million for the following fiscal year.
This framework explains in part why the stock supports a high multiple while remaining buoyed by rising expected earnings. On a technical level, the support at €184.00 is now approximately 14% below the current price, while the resistance at €218.80 remains the threshold to break for the advance to continue.
